Charles Schwab Investment Management Inc. Acquires 11,355 Shares of Artiva Biotherapeutics, Inc. $ARTV

Charles Schwab Investment Management Inc. increased its holdings in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) by 26.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,881 shares of the company’s stock after acquiring an additional 11,355 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.23% of Artiva Biotherapeutics worth $165,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ARTV. Wells Fargo & Company MN lifted its holdings in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares during the period. BNP Paribas Financial Markets increased its position in Artiva Biotherapeutics by 262.1% in the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock worth $100,000 after buying an additional 7,151 shares during the last quarter. Deutsche Bank AG purchased a new stake in Artiva Biotherapeutics in the fourth quarter worth $216,000. Barclays PLC increased its position in Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after buying an additional 4,545 shares during the last quarter. Finally, Northern Trust Corp increased its position in Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after buying an additional 4,335 shares during the last quarter.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $3.11 on Friday. Artiva Biotherapeutics, Inc. has a 52-week low of $1.47 and a 52-week high of $17.31. The stock has a fifty day moving average of $2.59 and a 200 day moving average of $2.74.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.03). Equities analysts predict that Artiva Biotherapeutics, Inc. will post -4.95 earnings per share for the current fiscal year.

Insider Transactions at Artiva Biotherapeutics

In related news, CEO Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock in a transaction on Friday, August 15th. The stock was sold at an average price of $2.73, for a total transaction of $69,615.00. Following the completion of the sale, the chief executive officer owned 386,693 shares of the company’s stock, valued at approximately $1,055,671.89. This trade represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 21.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Needham & Company LLC decreased their target price on Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 15th. HC Wainwright raised Artiva Biotherapeutics to a “buy” rating and set a $12.00 target price for the company in a research report on Wednesday, June 11th. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $17.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.